Product category:
Measurement and Quality Software and SPC
News Release from: IDBS | Subject: ActivityBase
Edited by the Manufacturingtalk Editorial
Team on 01 October 2004
ActivityBase Choosen For Drug Discovery
Operations
The Cancer Research UK Centre for Cancer Therapeutics has chosen ActivityBase from IDBS as their data management platform for its drug discovery operations.
The Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research has chosen ActivityBase from IDBS as their data management platform for its drug discovery operations The need for direct access to a comprehensive drug discovery data resource for the Centre's academics, clinicians and management, as well as its many collaboration partners, was a key factor in the selection of ActivityBase from IDBS
This article was originally published on Manufacturingtalk on 13 Jul 2004 at 8.00am (UK)
Related stories
Ionix Pharmaceuticals Increases Efficiency
Ionix Pharmaceuticals Increases Efficiency with ActivityBase from IDBS
Cancer Research Technology chooses ActivityBase
Cancer Research Technology Ltd expands drug discovery infrastructure - ActivityBase chosen for data management
The Institute is part of the University of London and together with its hospital partner, the Royal Marsden NHS Foundation Trust, forms the largest cancer centre in Europe.
An academic institution significantly funded by charitable donations, The Institute of Cancer Research, with generous financial support from Cancer Research UK, operates a full-scale drug discovery programme at the forefront of world-class cancer research.
ActivityBase will underpin the discovery operations at The Institute's Centre for Cancer Therapeutics, encompassing basic research, biology, chemistry, high throughput screening and pharmacology.
Further reading
IDBS launches ActivityBase 5.3 and SARview 6.0
IDBS, provider of integrated data management, analysis and decision-making software for life sciences, today announced ActivityBase 5.3 and SARview 6.0.
IDBS launches ActivityBase XE
Revolutionary solution for high throughput screening data management
Professor Paul Workman, Centre Director at The Institute of Cancer Research, commented: "We are pleased to be working with ActivityBase to help accelerate our search for new drugs that are designed to act on new molecular targets responsible for various cancers.
The objective is to get these treatments to our cancer patients as rapidly as possible." Commenting on the reasons for selecting ActivityBase, Dr Wynne Aherne, compound screening team leader at the Centre for Cancer Therapeutics said: "We sought an adaptable informatics system to integrate all our compound information including ADME, pharmacokinetics and mass spectrometry data as well as primary and secondary screening results." Dr Aherne continued, "We have many collaborators in the pharmaceutical, biotechnology and academic sectors and need to share data with them in a straightforward and professional manner.
Our evaluation of ActivityBase has shown that the software will help us achieve all of these goals." "Communication between scientists, both within organisations and between discovery partners, is one of the keys to success in drug research," commented Neil Kipling, Chairman and CEO of IDBS.
"The Institute of Cancer Research is one of the world's leading research institutions and we are delighted that ActivityBase will facilitate the sharing of information between the Institute and its collaborators in order to accelerate progress in the fight against cancer.".
• IDBS: contact details and other news
• Email this article to a colleague
• Register for the free Manufacturingtalk email newsletter
• Manufacturingtalk Home Page
